Kevin D Read

List of Publications by Year
in descending order

70 papers	3,870 citations	147801 31 h-index	128289 60 g-index
74 all docs	74 docs citations	74 times ranked	5203 citing authors

#	Article	IF	Citations
1	Compounds enhancing human sperm motility identified using a high-throughput phenotypic screening platform. Human Reproduction, 2022, 37, 466-475.	0.9	6
2	Repositioning of a Diaminothiazole Series Confirmed to Target the Cyclin-Dependent Kinase CRK12 for Use in the Treatment of African Animal Trypanosomiasis. Journal of Medicinal Chemistry, 2022, 65, 5606-5624.	6.4	8
3	Optimization of TAM16, a Benzofuran That Inhibits the Thioesterase Activity of Pks13; Evaluation toward a Preclinical Candidate for a Novel Antituberculosis Clinical Target. Journal of Medicinal Chemistry, 2022, 65, 409-423.	6.4	15
4	A Systematic Study of the In Vitro Pharmacokinetics and Estimated Human In Vivo Clearance of Indole and Indazole-3-Carboxamide Synthetic Cannabinoid Receptor Agonists Detected on the Illicit Drug Market. Molecules, 2021, 26, 1396.	3.8	15
5	Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis. Journal of Medicinal Chemistry, 2021, 64, 5905-5930.	6.4	25
6	Preparation, biological & cheminformatics-based assessment of N2,N4-diphenylpyrimidine-2,4-diamine as potential Kinase-targeted antimalarials. Bioorganic and Medicinal Chemistry, 2021, 46, 116348.	3.0	5
7	Spirocycle MmpL3 Inhibitors with Improved hERG and Cytotoxicity Profiles as Inhibitors of Mycobacterium tuberculosis Growth. ACS Omega, 2021, 6, 2284-2311.	3.5	19
8	Setting Our Sights on Infectious Diseases. ACS Infectious Diseases, 2020, 6, 3-13.	3.8	17
9	Targeting N-myristoylation for therapy of B-cell lymphomas. Nature Communications, 2020, 11, 5348.	12.8	35
10	Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both inÂvitro and inÂvivo trypanocidal efficacy. European Journal of Medicinal Chemistry, 2020, 207, 112849.	5.5	13
11	Identification and Optimization of a Series of 8-Hydroxy Naphthyridines with Potent In Vitro Antileishmanial Activity: Initial SAR and Assessment of In Vivo Activity. Journal of Medicinal Chemistry, 2020, 63, 9523-9539.	6.4	8
12	Identification of 6-amino-1H-pyrazolo[3,4-d]pyrimidines with in vivo efficacy against visceral leishmaniasis. RSC Medicinal Chemistry, 2020, 11, 1168-1177.	3.9	2
13	Discovery and Optimization of a Compound Series Active against Trypanosoma cruzi, the Causative Agent of Chagas Disease. Journal of Medicinal Chemistry, 2020, 63, 3066-3089.	6.4	8
14	Veterinary trypanocidal benzoxaboroles are peptidase-activated prodrugs. PLoS Pathogens, 2020, 16, e1008932.	4.7	16
15	Veterinary trypanocidal benzoxaboroles are peptidase-activated prodrugs. , 2020, 16, e1008932.		0
16	Veterinary trypanocidal benzoxaboroles are peptidase-activated prodrugs. , 2020, 16, e1008932.		0
17	Veterinary trypanocidal benzoxaboroles are peptidase-activated prodrugs. , 2020, 16, e1008932.		0
18	Veterinary trypanocidal benzoxaboroles are peptidase-activated prodrugs. , 2020, 16, e1008932.		0

#	Article	IF	Citations
19	A brain-permeable inhibitor of the neurodegenerative disease target kynurenine 3-monooxygenase prevents accumulation of neurotoxic metabolites. Communications Biology, 2019, 2, 271.	4.4	36
20	Substituted Aminoacetamides as Novel Leads for Malaria Treatment. ChemMedChem, 2019, 14, 1329-1335.	3.2	5
21	Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 7015-7020.	7.1	94
22	Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9318-9323.	7.1	119
23	Discovery of Soft-Drug Topical Tool Modulators of Sphingosine-1-phosphate Receptor 1 (S1PR1). ACS Medicinal Chemistry Letters, 2019, 10, 341-347.	2.8	5
24	Loss of CRMP2 O-GlcNAcylation leads to reduced novel object recognition performance in mice. Open Biology, 2019, 9, 190192.	3.6	17
25	Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis. Journal of Medicinal Chemistry, 2019, 62, 1180-1202.	6.4	33
26	Pharmacological Validation of N-Myristoyltransferase as a Drug Target in Leishmania donovani. ACS Infectious Diseases, 2019, 5, 111-122.	3.8	55
27	Initial Characterization and Toxicology of an Nmt Inhibitor in Development for Hematologic Malignancies. Blood, 2019, 134, 3362-3362.	1.4	4
28	2-Mercapto-Quinazolinones as Inhibitors of Type II NADH Dehydrogenase and Mycobacterium tuberculosis: Structureâ€“Activity Relationships, Mechanism of Action and Absorption, Distribution, Metabolism, and Excretion Characterization. ACS Infectious Diseases, 2018, 4, 954-969.	3.8	49
29	Chemical synthesis, characterisation and in vitro and in vivo metabolism of the synthetic opioid MT-45 and its newly identified fluorinated analogue 2F-MT-45 with metabolite confirmation in urine samples from known drug users. Forensic Toxicology, 2018, 36, 359-374.	2.4	26
30	Group-Based Optimization of Potent and Cell-Active Inhibitors of the von Hippelâ€“Lindau (VHL) E3 Ubiquitin Ligase: Structureâ€“Activity Relationships Leading to the Chemical Probe (2S,4R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol (VH298). Journal of Medicinal Chemistry, 2018, 61, 599-618.	6.4	106
31	A Molecular Hybridization Approach for the Design of Potent, Highly Selective, and Brain-Penetrant N-Myristoyltransferase Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 8374-8389.	6.4	41
32	Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB. Journal of Medicinal Chemistry, 2018, 61, 6592-6608.	6.4	43
33	2,4-Diamino-6-methylpyrimidines for the potential treatment of Chagasâ€™ disease. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3025-3030.	2.2	5
34	Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis. Nature, 2018, 560, 192-197.	27.8	112
35	Discovery of super soft-drug modulators of sphingosine-1-phosphate receptor 1. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3255-3259.	2.2	18
36	Pharmacokinetics of Î²-Lactam Antibiotics: Clues from the Past To Help Discover Long-Acting Oral Drugs in the Future. ACS Infectious Diseases, 2018, 4, 1439-1447.	3.8	26

#	Article	IF	Citations
37	Host-parasite co-metabolic activation of antitrypanosomal aminomethyl-benzoxaboroles. PLoS Pathogens, 2018, 14, e1006850.	4.7	26
38	Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need. Nature Reviews Microbiology, 2017, 15, 217-231.	28.6	315
39	Chemical Validation of Methionyl-tRNA Synthetase as a Druggable Target in Leishmania donovani. ACS Infectious Diseases, 2017, 3, 718-727.	3.8	22
40	Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi. Journal of Medicinal Chemistry, 2017, 60, 7284-7299.	6.4	31
41	Design and Synthesis of Brain Penetrant Trypanocidal N-Myristoyltransferase Inhibitors. Journal of Medicinal Chemistry, 2017, 60, 9790-9806.	6.4	14
42	Biochemical and Structural Characterization of Selective Allosteric Inhibitors of the Plasmodium falciparum Drug Target, Prolyl-tRNA-synthetase. ACS Infectious Diseases, 2017, 3, 34-44.	3.8	45
43	Essential but Not Vulnerable: Indazole Sulfonamides Targeting Inosine Monophosphate Dehydrogenase as Potential Leads against Mycobacterium tuberculosis. ACS Infectious Diseases, 2017, 3, 18-33.	3.8	77
44	Activation of Bicyclic Nitro-drugs by a Novel Nitroreductase (NTR2) in Leishmania. PLoS Pathogens, 2016, 12, e1005971.	4.7	73
45	Metabolomics and lipidomics reveal perturbation of sphingolipid metabolism by a novel anti-trypanosomal 3-(oxazolo[4,5-b]pyridine-2-yl)anilide. Metabolomics, 2016, 12, 1.	3.0	28
46	Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy. Journal of Medicinal Chemistry, 2016, 59, 9672-9685.	6.4	66
47	Hit-to-Lead Optimization of a Novel Class of Potent, Broad-Spectrum Trypanosomacides. Journal of Medicinal Chemistry, 2016, 59, 9686-9720.	6.4	30
48	Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage. Scientific Reports, 2016, 6, 35351.	3.3	72
49	Potent and selective chemical probe of hypoxic signalling downstream of HIF-Î± hydroxylation via VHL inhibition. Nature Communications, 2016, 7, 13312.	12.8	167
50	Trisubstituted Pyrimidines as Efficacious and Fast-Acting Antimalarials. Journal of Medicinal Chemistry, 2016, 59, 6101-6120.	6.4	13
51	The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis. ELife, 2016, 5, .	6.0	67
52	Discovery of Inhibitors of Trypanosoma brucei by Phenotypic Screening of a Focused Protein Kinase Library. ChemMedChem, 2015, 10, 1809-1820.	3.2	15
53	Development of Smallâ€Molecule Trypanosoma brucei Nâ€Myristoyltransferase Inhibitors: Discovery and Optimisation of a Novel Binding Mode. ChemMedChem, 2015, 10, 1821-1836.	3.2	20
54	Development of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas Disease. PLoS Neglected Tropical Diseases, 2015, 9, e0004014.	3.0	43

#	Article	IF	Citations
55	A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature, 2015, 522, 315-320.	27.8	353
56	Discovery of Indoline-2-carboxamide Derivatives as a New Class of Brain-Penetrant Inhibitors of Trypanosoma brucei. Journal of Medicinal Chemistry, 2015, 58, 7695-7706.	6.4	28
57	Lead Optimization of a Pyrazole Sulfonamide Series of Trypanosoma brucei N-Myristoyltransferase Inhibitors: Identification and Evaluation of CNS Penetrant Compounds as Potential Treatments for Stage 2 Human African Trypanosomiasis. Journal of Medicinal Chemistry, 2014, 57, 9855-9869.	6.4	57
58	Discovery of Î²2 Adrenergic Receptor Ligands Using Biosensor Fragment Screening of Tagged Wild-Type Receptor. ACS Medicinal Chemistry Letters, 2013, 4, 1005-1010.	2.8	65
59	The R Enantiomer of the Antitubercular Drug PA-824 as a Potential Oral Treatment for Visceral Leishmaniasis. Antimicrobial Agents and Chemotherapy, 2013, 57, 4699-4706.	3.2	62
60	The Anti-Trypanosome Drug Fexinidazole Shows Potential for Treating Visceral Leishmaniasis. Science Translational Medicine, 2012, 4, 119re1.	12.4	126
61	Combining PET Biodistribution and Equilibrium Dialysis Assays to Assess the Free Brain Concentration and BBB Transport of CNS Drugs. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 874-883.	4.3	53
62	Discovery of a Novel Class of Orally Active Trypanocidal N-Myristoyltransferase Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 140-152.	6.4	102
63	Target Validation: Linking Target and Chemical Properties to Desired Product Profile. Current Topics in Medicinal Chemistry, 2011, 11, 1275-1283.	2.1	99
64	Optimisation of the Antiâ€Trypanosoma brucei Activity of the Opioid Agonist U50488. ChemMedChem, 2011, 6, 1832-1840.	3.2	7
65	Identification of a Î¹-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis. Biochemical Pharmacology, 2010, 80, 1478-1486.	4.4	69
66	N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. Nature, 2010, 464, 728-732.	27.8	272
67	Assessing brain free fraction in early drug discovery. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 337-344.	3.3	65
68	Receptor Occupancy and Brain Free Fraction. Drug Metabolism and Disposition, 2009, 37, 753-760.	3.3	114
69	The relationship between sodium channel inhibition and anticonvulsant activity in a model of generalised seizure in the rat. Epilepsy Research, 2009, 85, 96-106.	1.6	41
70	Central Nervous System Drug Disposition: The Relationship between in Situ Brain Permeability and Brain Free Fraction. Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 205-213.	2.5	247